Taken together, these results implicate a critical role for IL‐13 in the aftermath of SARS‐CoV‐2 mild infections and mRNA vaccinations, conferring protection against airway directed, atopic side reactions that occur in mildly experienced COVID‐19. Here, IL13 is linked to infection.